AU2012284361B2 - Treatment for hypoxia - Google Patents

Treatment for hypoxia Download PDF

Info

Publication number
AU2012284361B2
AU2012284361B2 AU2012284361A AU2012284361A AU2012284361B2 AU 2012284361 B2 AU2012284361 B2 AU 2012284361B2 AU 2012284361 A AU2012284361 A AU 2012284361A AU 2012284361 A AU2012284361 A AU 2012284361A AU 2012284361 B2 AU2012284361 B2 AU 2012284361B2
Authority
AU
Australia
Prior art keywords
subject
hmf
administered
hypoxia
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012284361A
Other languages
English (en)
Other versions
AU2012284361A2 (en
AU2012284361A1 (en
Inventor
Warren Stern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AesRX LLC
Original Assignee
AesRX LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AesRX LLC filed Critical AesRX LLC
Publication of AU2012284361A1 publication Critical patent/AU2012284361A1/en
Publication of AU2012284361A2 publication Critical patent/AU2012284361A2/en
Application granted granted Critical
Publication of AU2012284361B2 publication Critical patent/AU2012284361B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012284361A 2011-07-15 2012-07-12 Treatment for hypoxia Ceased AU2012284361B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161508260P 2011-07-15 2011-07-15
US61/508,260 2011-07-15
PCT/US2012/046427 WO2013012670A1 (en) 2011-07-15 2012-07-12 Treatment for hypoxia

Publications (3)

Publication Number Publication Date
AU2012284361A1 AU2012284361A1 (en) 2014-01-30
AU2012284361A2 AU2012284361A2 (en) 2014-02-13
AU2012284361B2 true AU2012284361B2 (en) 2016-11-17

Family

ID=46551919

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012284361A Ceased AU2012284361B2 (en) 2011-07-15 2012-07-12 Treatment for hypoxia

Country Status (7)

Country Link
US (1) US9918958B2 (enExample)
EP (1) EP2731602A1 (enExample)
JP (1) JP2014520854A (enExample)
AU (1) AU2012284361B2 (enExample)
BR (1) BR112014000889A2 (enExample)
CA (1) CA2841954C (enExample)
WO (1) WO2013012670A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016043849A2 (en) 2014-07-24 2016-03-24 Global Blood Therapeutics, Inc. Compounds for treating acute respiratory distress syndrome or a negative effect thereof
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
JP7265237B2 (ja) * 2017-07-27 2023-04-26 共栄化学工業株式会社 毛髪用組成物及び皮膚外用組成物
EP4415698A1 (en) * 2021-10-11 2024-08-21 D-Cap Llc 5-hydroxymethylfurfural for the treatment of mitochondrial dysfunction
US11458144B1 (en) 2021-12-23 2022-10-04 King Abdulaziz University Methods for using 5-HMF analogs with increased solubility to inhibit or reverse RBC sickling
CN117085005A (zh) * 2023-10-08 2023-11-21 山东省科学院生物研究所 5-羟甲基-2-呋喃甲酸在制备促血管生成相关产品中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011146471A1 (en) * 2010-05-18 2011-11-24 Aesrx Llc Treatment for altitudinal hypoxia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2179987E (pt) 2002-12-04 2013-03-11 Univ Virginia Commonwealth Utilização de derivados carbaldeído heterocíclicos contra a anemia falciforme
EP2255623A1 (en) * 2009-05-26 2010-12-01 Volker Wagner-Solbach Plant nutriments

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011146471A1 (en) * 2010-05-18 2011-11-24 Aesrx Llc Treatment for altitudinal hypoxia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LI M, et al., 'The protective role of 5-HMF against hypoxic injury,' Cell Stress and Chaperones, (2011), Vol 16, pp 267-273. *
LI M, et al., 'The protective role of 5-hyroxymethyl-2-furfural (5-HMF) against hypobaric hypoxia,' Cell Stress and Chaperones, (published online 15 April 2011), Vol 16, pp 529-537 *

Also Published As

Publication number Publication date
EP2731602A1 (en) 2014-05-21
CA2841954A1 (en) 2013-01-24
BR112014000889A2 (pt) 2017-10-31
AU2012284361A2 (en) 2014-02-13
CA2841954C (en) 2020-05-05
US9918958B2 (en) 2018-03-20
US20130018092A1 (en) 2013-01-17
JP2014520854A (ja) 2014-08-25
AU2012284361A1 (en) 2014-01-30
WO2013012670A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
US11723589B2 (en) Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
AU2012284361B2 (en) Treatment for hypoxia
US20120101073A1 (en) Novel Method For Treating Breathing Disorders or Diseases
JP5712452B2 (ja) 診断された呼吸疾患を有する患者もしくは診断未確定の呼吸疾患を有する患者におけるオピオイド鎮痛薬の投与に関連する危険性を減少するための方法および組成
BG107185A (bg) Метод за получаване на лекарствено средство за лечение на сексуална дисфункция с апоморфин при определени нива на плазмена концентрация
US9125900B2 (en) Pharmaceutical composition
US11253506B2 (en) Compounds, compositions and methods for preventing and/or treating chlorine inhalation toxicity and/or injury
RU2738885C1 (ru) Противо-SARS-CoV-2 вирусное средство Антипровир
JP5916717B2 (ja) 高地低酸素症の処置
WO2021221537A1 (ru) Противо-sars-cov-2 вирусное средство антипровир
Chediak et al. Effect of histamine on tracheal mucosal perfusion, water content and airway smooth muscle in sheep
US20200345761A1 (en) Preventive and/or therapeutic agent for dementia
KR102606504B1 (ko) 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
CN112569220B (zh) 四氢次大麻酚在制备用于治疗肺动脉高压药物中的应用及含有四氢次大麻酚的药物组合物
US8980849B2 (en) Compositions and methods for treating pulmonary hypertension
US20130096099A1 (en) Method of treating brain cancer
JP4853837B2 (ja) 過敏性腸症候群治療剤
Gaudy et al. Effect of a new analeptic drug, almitrine, on fentanyl-induced respiratory depression and analgesia in man
Frank A 32-Year-Old Woman Undergoing Laparoscopic Ovarian Cystectomy
CN119326892A (zh) Pad4抑制剂用于制备预防和治疗化疗药物引发的周围神经病变的药物的用途
CN118976093A (zh) 一种γ-谷氨酰半胱氨酸用于防止化疗药物引发的周围神经细胞损伤的用途
WO2024194263A1 (en) Serotonin 5ht2a receptor antagonist for use in treating side effects resulting form mu opioid receptor agonist overdose
Trialist CMEddddddddddddddddddddddd

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 JAN 2014

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired